{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:45:54Z","timestamp":1776951954027,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1245\/s10434-025-17517-0","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T11:27:34Z","timestamp":1748604454000},"page":"5784-5794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis"],"prefix":"10.1245","volume":"32","author":[{"given":"Justin M.","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ava","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biren","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricarda","family":"Tomlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"17517_CR1","doi-asserted-by":"publisher","unstructured":"Elias D, Fran\u00e7ois No\u00ebl Gilly, Florent Boutitie, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-68. https:\/\/doi.org\/10.1200\/jco.2009.23.9285","DOI":"10.1200\/jco.2009.23.9285"},{"key":"17517_CR2","doi-asserted-by":"publisher","unstructured":"McMullen JRW, Selleck M, Wall NR, Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481-43490. https:\/\/doi.org\/10.18632\/oncotarget.16480","DOI":"10.18632\/oncotarget.16480"},{"key":"17517_CR3","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s-Guiral D, H\u00fcbner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1). https:\/\/doi.org\/10.1038\/s41572-021-00326-6","DOI":"10.1038\/s41572-021-00326-6"},{"key":"17517_CR4","doi-asserted-by":"publisher","unstructured":"Smeenk RM, Velthuysen MLF van, Verwaal VJ, Zoetmulder F a. N. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196-201. https:\/\/doi.org\/10.1016\/j.ejso.2007.04.002","DOI":"10.1016\/j.ejso.2007.04.002"},{"issue":"2","key":"17517_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3747\/co.22.2058","volume":"22","author":"P Dub\u00e9","year":"2015","unstructured":"Dub\u00e9 P, Sideris L, Law CK, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22(2):100\u201312. https:\/\/doi.org\/10.3747\/co.22.2058.","journal-title":"Curr Oncol."},{"issue":"2","key":"17517_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s13193-016-0498-0","volume":"7","author":"SJ Valle","year":"2016","unstructured":"Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL. Hyperthermic intraperitoneal chemotherapy (hipec) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol. 2016;7(2):152\u20139. https:\/\/doi.org\/10.1007\/s13193-016-0498-0.","journal-title":"Indian J Surg Oncol."},{"key":"17517_CR7","doi-asserted-by":"publisher","unstructured":"Young Ho Kim, Kim CH. Treatment for peritoneal metastasis of patients with colorectal cancer. Ann Coloproctol. 2021;37(6):425-433. https:\/\/doi.org\/10.3393\/ac.2021.00920.0131","DOI":"10.3393\/ac.2021.00920.0131"},{"key":"17517_CR8","doi-asserted-by":"publisher","unstructured":"Niels A. D. Guchelaar, Noordman BJ, Stijn L. W. Koolen, et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies. Drugs. 2023;83(2):159-180. https:\/\/doi.org\/10.1007\/s40265-022-01828-7","DOI":"10.1007\/s40265-022-01828-7"},{"issue":"3","key":"17517_CR9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1245\/s10434-020-09064-7","volume":"28","author":"Y Berger","year":"2020","unstructured":"Berger Y, Schuitevoerder D, Vining CC, et al. Novel application of iterative hyperthermic intraperitoneal chemotherapy for unresectable peritoneal metastases from high-grade appendiceal ex-goblet adenocarcinoma. Ann Surg Oncol. 2020;28(3):1777\u201385. https:\/\/doi.org\/10.1245\/s10434-020-09064-7.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17517_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10434-004-1167-z","volume":"12","author":"VJ Verwaal","year":"2004","unstructured":"Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FAN. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2004;12(1):65\u201371. https:\/\/doi.org\/10.1007\/s10434-004-1167-z.","journal-title":"Ann Surg Oncol."},{"key":"17517_CR11","unstructured":"Anwar A, Kasi A. Peritoneal Cancer. NIH.gov. Published 30 April 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562138\/#article-27025.s11"},{"issue":"3","key":"17517_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/cancers15030607","volume":"15","author":"EM Pasqual","year":"2023","unstructured":"Pasqual EM, Londero AP, Robella M, et al. Repeated cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in selected patients affected by peritoneal metastases: Italian PSM Oncoteam evidence. Cancers. 2023;15(3):607\u2013607. https:\/\/doi.org\/10.3390\/cancers15030607.","journal-title":"Cancers."},{"key":"17517_CR13","doi-asserted-by":"publisher","unstructured":"Fran\u00e7ois Quenet, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2021;22(2):256-266. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4","DOI":"10.1016\/s1470-2045(20)30599-4"},{"issue":"7","key":"17517_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","volume":"158","author":"A Arjona-S\u00e1nchez","year":"2023","unstructured":"Arjona-S\u00e1nchez A, Espinosa-Redondo E, Guti\u00e9rrez-Calvo A, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer. JAMA Surgery. 2023;158(7):683\u2013683. https:\/\/doi.org\/10.1001\/jamasurg.2023.0662.","journal-title":"JAMA Surgery."},{"issue":"2","key":"17517_CR15","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1503\/cjs.001619","volume":"64","author":"E Benzaquen","year":"2021","unstructured":"Benzaquen E, Wang Y, Wiseman S, et al. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study. Can J Surg. 2021;64(2):E111\u20138. https:\/\/doi.org\/10.1503\/cjs.001619.","journal-title":"Can J Surg."},{"issue":"5","key":"17517_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","volume":"21","author":"KK Turaga","year":"2014","unstructured":"Turaga KK, Levine EA, Barone R, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014;21(5):1501\u20135. https:\/\/doi.org\/10.1245\/s10434-013-3061-z.","journal-title":"Ann Surg Oncol."},{"key":"17517_CR17","doi-asserted-by":"publisher","unstructured":"Garrett Michael Nash, Garcia-Aguilar J, Paty P, et al. Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial. J Clin Oncol. 2023;41(4_suppl):160-160. https:\/\/doi.org\/10.1200\/jco.2023.41.4_suppl.160","DOI":"10.1200\/jco.2023.41.4_suppl.160"},{"issue":"4","key":"17517_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","volume":"218","author":"EA Levine","year":"2014","unstructured":"Levine EA, Stewart JM, Shen P, Russell GB, Loggie BW, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573\u201385. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2013.12.013.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"17517_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1515\/pp-2017-0003","volume":"2","author":"K Van","year":"2017","unstructured":"Van K, Lemoine L, Sugarbaker P. Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice. Pleura Peritoneum. 2017;2(2):63\u201372. https:\/\/doi.org\/10.1515\/pp-2017-0003.","journal-title":"Pleura Peritoneum."},{"key":"17517_CR20","doi-asserted-by":"publisher","unstructured":"Hendrikson J, Tan JW, Ong CAJ. Can biomarkers predict chemosensitivity in CRS-HIPEC patients? Colorectal Cancer. 2019;8(4). https:\/\/doi.org\/10.2217\/crc-2019-0015","DOI":"10.2217\/crc-2019-0015"},{"issue":"5","key":"17517_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/bjc.2015.18","volume":"112","author":"R Kwakman","year":"2015","unstructured":"Kwakman R, de Cuba EMV, de Winter JP, et al. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer. 2015;112(5):851\u20136. https:\/\/doi.org\/10.1038\/bjc.2015.18.","journal-title":"Br J Cancer."},{"key":"17517_CR22","doi-asserted-by":"publisher","unstructured":"Shannon NB, Tan JWS, Tan HL, et al. A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis. Sci Rep. 2019;9(1). https:\/\/doi.org\/10.1038\/s41598-019-46819-z","DOI":"10.1038\/s41598-019-46819-z"},{"key":"17517_CR23","doi-asserted-by":"publisher","unstructured":"Jin J, Yoshimura K, Matheus Sewastjanow-Silva, Song S, Ajani JA. Challenges and prospects of patient-derived xenografts for cancer research. Cancers. 2023;15(17):4352-4352. https:\/\/doi.org\/10.3390\/cancers15174352","DOI":"10.3390\/cancers15174352"},{"issue":"1","key":"17517_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):1\u201324. https:\/\/doi.org\/10.1038\/s41392-023-01419-2.","journal-title":"Signal Transduct Target Ther."},{"key":"17517_CR25","doi-asserted-by":"publisher","unstructured":"Stevens MM, Kimmerling RJ, Selim Olcum, et al. Cellular mass response to therapy correlates with clinical response for a range of malignancies. JCO Precis Oncol. 2024;8(8). https:\/\/doi.org\/10.1200\/po.23.00349","DOI":"10.1200\/po.23.00349"},{"issue":"5","key":"17517_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","volume":"33","author":"L Lemoine","year":"2017","unstructured":"Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperthermia. 2017;33(5):582\u201392. https:\/\/doi.org\/10.1080\/02656736.2017.1291999.","journal-title":"Int J Hyperthermia."},{"issue":"2","key":"17517_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"key":"17517_CR28","unstructured":"EORTC. EORTC Quality of Life website | EORTC Quality of Life Group website. EORTC \u2013 Quality of Life. Published 2001. https:\/\/qol.eortc.org\/"},{"issue":"3","key":"17517_CR29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA de Souza","year":"2016","unstructured":"de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2016;123(3):476\u201384. https:\/\/doi.org\/10.1002\/cncr.30369.","journal-title":"Cancer."},{"key":"17517_CR30","unstructured":"Travera Inc. Clinical Platform and Workflow. TRAVERA. Published 2024. https:\/\/www.travera.com\/clinical-platform-and-workflow"},{"issue":"1","key":"17517_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jmp5010001","volume":"5","author":"KR Bisson","year":"2024","unstructured":"Bisson KR, Won JR, Beharry A, et al. Novel approach to proficiency testing highlights key practice variations in cancer biomarker delivery. J Mol Pathol. 2024;5(1):1\u201310. https:\/\/doi.org\/10.3390\/jmp5010001.","journal-title":"J Mol Pathol."},{"key":"17517_CR32","doi-asserted-by":"publisher","unstructured":"Petter Fr\u00fchling, Ghanipour L, Dranichnikov P, Malin Enblad, Helgi Birgisson, Cashin PH. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy with single drug versus multiple drug treatment for colorectal cancer with peritoneal metastases: an observational cohort study. J Gastrointest Oncol. 2021;12(2):516-526. https:\/\/doi.org\/10.21037\/jgo-20-494","DOI":"10.21037\/jgo-20-494"},{"issue":"1","key":"17517_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1245\/s10434-023-14422-2","volume":"31","author":"N Bhutiani","year":"2023","unstructured":"Bhutiani N, Grotz TE, Concors SJ, et al. Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent mucinous appendiceal adenocarcinoma: a viable treatment strategy with demonstrable benefit. Ann Surg Oncol. 2023;31(1):614\u201321. https:\/\/doi.org\/10.1245\/s10434-023-14422-2.","journal-title":"Ann Surg Oncol."},{"key":"17517_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jso.23545","volume":"109","author":"C Huang","year":"2014","unstructured":"Huang C, Feng J, Yang X, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center. J Surg Oncol. 2014;109:730\u20139.","journal-title":"J Surg Oncol."},{"issue":"3","key":"17517_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1245\/s10434-013-3407-6","volume":"21","author":"A Sardi","year":"2014","unstructured":"Sardi A, Jimenez W, Nieroda C, Sittig M, Shankar S, Gushchin V. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21(3):908\u201314. https:\/\/doi.org\/10.1245\/s10434-013-3407-6.","journal-title":"Ann Surg Oncol."},{"key":"17517_CR36","doi-asserted-by":"publisher","unstructured":"Carrato A. Precision medicine: UGT1A1 genotyping to better manage irinotecan-induced toxicity. JCO Oncol Pract. 2022;18(4). https:\/\/doi.org\/10.1200\/op.21.00858","DOI":"10.1200\/op.21.00858"},{"key":"17517_CR37","unstructured":"Al-kasspooles M. Comparing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Clinicaltrials.gov. Published 2017. https:\/\/clinicaltrials.gov\/study\/NCT03073694"},{"issue":"1","key":"17517_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"Jung J, Seol HS, Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res Treat. 2018;50(1):1\u201310. https:\/\/doi.org\/10.4143\/crt.2017.307.","journal-title":"Cancer Res Treat."},{"issue":"10","key":"17517_CR39","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.ejso.2020.04.019","volume":"46","author":"EC Hulshof","year":"2020","unstructured":"Hulshof EC, Lurvink RJ, Caserta N, et al. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. Eur J Surg Oncol. 2020;46(10):1925\u201331. https:\/\/doi.org\/10.1016\/j.ejso.2020.04.019.","journal-title":"Eur J Surg Oncol."},{"issue":"11","key":"17517_CR40","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/biom14111359","volume":"14","author":"T Martinez-Bernabe","year":"2024","unstructured":"Martinez-Bernabe T, Pons DG, Oliver J, Sastre-Serra J. Oxidative phosphorylation as a predictive biomarker of oxaliplatin response in colorectal cancer. Biomolecules. 2024;14(11):1359\u20131359. https:\/\/doi.org\/10.3390\/biom14111359.","journal-title":"Biomolecules."},{"issue":"8","key":"17517_CR41","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3390\/cancers12082058","volume":"12","author":"M Sfakianaki","year":"2020","unstructured":"Sfakianaki M, Papadaki C, Tzardi M, et al. PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer. Cancers. 2020;12(8):2058. https:\/\/doi.org\/10.3390\/cancers12082058.","journal-title":"Cancers."},{"issue":"7","key":"17517_CR42","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1535-7163.mct-11-0937","volume":"11","author":"MK Kim","year":"2012","unstructured":"Kim MK, Osada T, Barry WT, et al. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther. 2012;11(7):1500\u20139. https:\/\/doi.org\/10.1158\/1535-7163.mct-11-0937.","journal-title":"Mol Cancer Ther."},{"key":"17517_CR43","doi-asserted-by":"publisher","unstructured":"Yue T, Liu X, Zuo S, et al. BCL2A1 and CCL18 are predictive biomarkers of cisplatin chemotherapy and immunotherapy in colon cancer patients. Front Cell Dev Biol. 2022;9. https:\/\/doi.org\/10.3389\/fcell.2021.799278","DOI":"10.3389\/fcell.2021.799278"},{"key":"17517_CR44","doi-asserted-by":"publisher","unstructured":"Kimmerling RJ, Stevens MM, Selim Olcum, et al. A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. Commun Biol. 2022;5(1). https:\/\/doi.org\/10.1038\/s42003-022-04270-3","DOI":"10.1038\/s42003-022-04270-3"},{"key":"17517_CR45","unstructured":"Travera Inc. Available Drugs for Testing. TRAVERA. Published 2024. https:\/\/www.travera.com\/drugs"},{"issue":"1","key":"17517_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2020","unstructured":"Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2020;28(1):258\u201364. https:\/\/doi.org\/10.1245\/s10434-020-08739-5.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"17517_CR47","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/bjs\/znad228","volume":"110","author":"RAG van Eerden","year":"2023","unstructured":"van Eerden RAG, de Boer NL, van Kooten JP, et al. Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases. Br J Surg. 2023;110(11):1502\u201310. https:\/\/doi.org\/10.1093\/bjs\/znad228.","journal-title":"Br J Surg."},{"key":"17517_CR48","doi-asserted-by":"publisher","unstructured":"Sipok A, Sardi A, Nieroda C, King MC, Sittig M, Vadim Gushchin. Comparison of survival in patients with isolated peritoneal carcinomatosis from colorectal cancer treated with cytoreduction and melphalan or mitomycin-C as hyperthermic intraperitoneal chemotherapy agent. Int J Surg Oncol. 2018;2018:1-9. https:\/\/doi.org\/10.1155\/2018\/1920276","DOI":"10.1155\/2018\/1920276"},{"issue":"4","key":"17517_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226(4):434\u201343. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.027.","journal-title":"J Am Coll Surg."},{"issue":"8","key":"17517_CR50","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","volume":"15","author":"JH Stewart","year":"2008","unstructured":"Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15(8):2137\u201345. https:\/\/doi.org\/10.1245\/s10434-008-9967-1.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:57:46Z","timestamp":1751464666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["17517"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17517-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}